Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension

Journal of Hypertension

Volumn 17, Issue 8, 1999, Pages 1203-1207

  Lip, Gregory Y H ^a   Blann, Andrew D ^a   Beevers, D Gareth ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Endothelial dysfunction; Isolated systolic hypertension; Prothrombotic

Indexed keywords

D DIMER; FIBRINOGEN; LIPOPROTEIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD RHEOLOGY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; ENDOTHELIUM INJURY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERCOAGULABILITY; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PLASMA VISCOSITY; PRIORITY JOURNAL; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0032803471     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917080-00021     Document Type: Article

References (12)

1. 1 Lip GYH, Beevers DG. Abnormalities of rheology and coagulation hypertension. J Hum Hypertens 1994; 8:693-701.
2. 2 Lee AJ, The role ot rheology and haemostatic factors in hypertension. J Human Hypertens 1997; 11:767-776.
3. 3 SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older parsons with isolated systolic hypertension. JAMA 1991; 265:3255-3264.
4. 4 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
5. 5 Lichtenstein MJ, Shipley MJ, Rosa G. Systolic and diastolic blood pressure as predictors of coronary heart disease in the Whitehall Study. BMJ 1985; 291:243-245.
6. 6 Kannel WB, Gordon T, Schwarz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. Am J Cardiol 1971 ; 27:335-345.
7. 7 MacMahon S, Peto R, Cutler R, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Lancet 1990; 335:765-774.
8. 8 Fisher CM. The ascendancy of diastolic blood pressure over systolic. Lancet 1985; 2:1349-1350.
9. 9 Lip GYH, Blann AD, Jones AF, Yip PL, Beevers DG. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80:1566-1571.
10. 10 Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coronary Artery Dis 1996; 7:143-147.
11. 11 Verhaar MC, Beutler JJ, Gaillard CA, Koomans IJA, Fijnheer R, Rabelink TJ. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens 1998; 16:45-50.
12. 12 Kloczko J, Wojtukiewicz MZ, Bielgwiec M, Galar M, Tarasow E. von Willebrand factor antigen and fibronectin in essential hypertension, Thromb Res 1995; 79:331-336.